Post-earnings recap
Reported
Thu, Mar 7, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Sarepta Therapeutics reported a significant loss per share, which contributed to a 3.51% decline in stock price. The lack of revenue figures and guidance suggests uncertainty about the company's near-term performance. Investors may be concerned about the company's ability to generate revenue as it continues to focus on its clinical trials.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.36 | N/A | -529.33% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious outlook due to the lack of revenue guidance. They emphasized their commitment to advancing clinical programs.
Management did not provide specific guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.